Table 3.
Demographical and clinical characteristics of the study group according to T cell response to SAR-Cov-2 protein N.
| DP response (n = 15) | No DP response (n = 15) | p | |||
|---|---|---|---|---|---|
| Age (years) | 63 | (44–69) | 63 | (43–66) | 0.539 |
| Sex (male) | 13 | (86.7) | 9 | (60.0) | 0.215 |
| Previous medical history | |||||
| Diabetes mellitus | 7 | (46.7) | 5 | (33.3) | 0.710 |
| Hypertension | 9 | (60.0) | 11 | (73.3) | 0.700 |
| ACE inhibitors or ARB | 5 | (33.3) | 8 | (60.0) | 0.272 |
| Clinical characteristics | |||||
| Non-severe COVID-19a | 14 | (93.3) | 12 | (80.0) | 0.598 |
| Hospital admission | 13 | (86.7) | 12 | (80.0) | p > 0.99 |
| COVID-19 specific therapy | |||||
| Lopinavir | 8 | (53.3) | 12 | (80.0) | 0.245 |
| Interferon beta | 4 | (26.7) | 6 | (40) | 0.700 |
| Hydroxychloroquine | 13 | (86.7) | 14 | (93.3) | p > 0.99 |
| Azithromycin | 5 | (33.3) | 8 | (53.3) | 0.462 |
| Tocilizumab | 1 | (6.7) | 1 | (6.7) | p > 0.99 |
| Corticosteroids (boluses) | 0 | (0.0) | 2 | (13.3) | 0.483 |
| Immunosuppression at baseline | (n = 8) | (n = 7) | |||
| Tacrolimus | 4 | (50) | 7 | (100) | 0.077 |
| Cyclosporine | 1 | (12.5) | 0 | (0.0) | p > 0.99 |
| Mycophenolate | 4 | (50.0) | 3 | (42.9) | p > 0.99 |
| Corticosteroids (maintenance) | 1 | (12.5) | 0 | (0.0) | p > 0.99 |
| Everolimus | 3 | (37.5) | 1 | (14.3) | 0.569 |
| Immunosuppression at month 12 | (n = 8) | (n = 7) | |||
| Tacrolimus | 4 | (40.0) | 7 | (100) | 0.077 |
| Tacrolimus trough levels (ng/mL), n = 11 | 3.6 | (2.1–6.6) | 4.2 | (1.9–4.7) | p > 0.99 |
| Mycophenolate | 2 | (25.0) | 1 | (14.3) | p > 0.99 |
| Everolimus | 3 | (37.5) | 3 | (42.9) | p > 0.99 |
| Everolimus trough levels (ng/mL), n = 6 | 3.3 | (2.1–6.6) | 3.2 | (2.7–3.2) | p > 0.99 |
| Interval since transplantation (years) | 6.9 | (3.2–18.9) | 2.4 | (1.7–8.4) | p = 0.19 |
Data are expressed as the median (interquartile range) or n (%).
DP: patients with both CD4+ and CD8+ positive response to protein N.
a
Severe COVID-19 was defined as the requirement for respiratory support or admission to the intensive care unit.